TapewireFind a company

person · Reporting owner

Davidson Matt

Disclosed activity across 2 companies

Tapewire entity
37606
SEC CIK
0001741937

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ADIAL PHARMACEUTICALS, INC.ADIL · Entity 7742Director · Chief Development OfficerJune 11, 2026June 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADIAL PHARMACEUTICALS, INC.

Report date June 11, 2026 · Filed June 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect61,647 Reported balance After 2026-06-11 transaction · row 1 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 1 · 2026-06-11 · Grant · Acquired 61,647 · Balance 61,647

F1: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

Common StockSEC Table I · non-derivativeDirect297,491 Reported balance After 2026-06-12 transaction · row 3 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 3 · 2026-06-12 · Grant · Acquired 232,417 · Balance 297,491

F4: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.

Common StockSEC Table I · non-derivativeIndirectBy Matt and Alli Davidson Trust3,427 Reported balance After 2026-06-11 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2026-06-11 · Grant · Acquired 3,427 · Balance 3,427

F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F3: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F6: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust.

Series A Preferred StockSEC Table I · non-derivativeDirect1,822.13 Reported balance After 2026-06-11 transaction · row 4
1 source row

Row 4 · 2026-06-11 · Grant · Acquired 1,822.13 · Balance 1,822.13

F1: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F5: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.

Series A Preferred StockSEC Table I · non-derivativeIndirectBy Matt and Alli Davidson Trust1,923.428 Reported balance After 2026-06-11 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 5 · 2026-06-11 · Grant · Acquired 101.298 · Balance 1,923.428

F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F3: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F5: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.

F6: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.89 · Expires 2036-06-12Direct232,417 Reported balance After 2026-06-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-06-12 · Grant · Acquired 232,417 · Balance 232,417

F7: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F2: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F3: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F4: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.

F5: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.

F6: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust.

F7: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Verrica Pharmaceuticals Inc.

Report date September 05, 2019 · Filed September 09, 2019

Section 16 reporting ended · disclosed 2019-09-09. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,556,179 Ending reported balance After 2019-09-09 transaction · row 5
5 source rows · reconciled sequence

Row 1 · 2019-09-05 · Sale · Disposed 3,100 · Balance 2,572,393

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Row 2 · 2019-09-06 · Sale · Disposed 3,802 · Balance 2,568,591

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Row 3 · 2019-09-06 · Sale · Disposed 4,712 · Balance 2,563,879

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Row 4 · 2019-09-06 · Sale · Disposed 1,400 · Balance 2,562,479

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F5: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Row 5 · 2019-09-09 · Sale · Disposed 6,300 · Balance 2,556,179

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F6: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.39 to $11.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.39 to $11.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 12, 2026 Filed Jun 16, 2026 10:36 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 GrantStock Option (Right to Buy) · Derivative 232,417 $0.00 Strike: $2.89 $0.00
Disclosure

SEC source: 0001213900-26-069037 · ownership.xml · derivative · entry 6

Davidson Matt · CIK 0001741937 · Director · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,417

Underlying: Common Stock · 232,417 shares

Expires 2036-06-12

F7 · kind: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.

F7 · price: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.

F7 · derivative.exercise_date: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.

Read SEC document
June 12, 2026 Filed Jun 16, 2026 10:36 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 GrantCommon Stock 232,417 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · Director · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 297,491

F4 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.

Read SEC document
June 11, 2026 Filed Jun 16, 2026 10:36 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 GrantSeries A Preferred Stock 101.298 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 5

Davidson Matt · CIK 0001741937 · Director · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Matt and Alli Davidson Trust

Disclosed balance after: 1,923.428

F2 · kind: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F3 · kind: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F5 · kind: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.

F2 · price: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F3 · price: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F5 · price: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.

F6 · ownership.nature: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust.

Read SEC document
June 11, 2026 Filed Jun 16, 2026 10:36 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 GrantSeries A Preferred Stock 1,822.13 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 4

Davidson Matt · CIK 0001741937 · Director · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,822.13

F1 · kind: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F2 · kind: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F5 · kind: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.

F1 · price: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F2 · price: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F5 · price: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.

Read SEC document
June 11, 2026 Filed Jun 16, 2026 10:36 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 GrantCommon Stock 3,427 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · Director · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Matt and Alli Davidson Trust

Disclosed balance after: 3,427

F2 · kind: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F3 · kind: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F3 · shares: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F2 · price: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F3 · price: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F6 · ownership.nature: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust.

Read SEC document
June 11, 2026 Filed Jun 16, 2026 10:36 UTC ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 GrantCommon Stock 61,647 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · Director · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,647

F1 · kind: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F2 · kind: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F1 · shares: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F1 · price: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F2 · price: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

Read SEC document
September 09, 2019 Filed Sep 9, 2019 22:27 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 6,300 $10.82 $68,166.00
Disclosure

SEC source: 0001209191-19-048940 · doc4.xml · nonDerivative · entry 5

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,556,179

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F6 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.39 to $11.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 06, 2019 Filed Sep 9, 2019 22:27 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 1,400 $12.07 $16,898.00
Disclosure

SEC source: 0001209191-19-048940 · doc4.xml · nonDerivative · entry 4

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,562,479

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 06, 2019 Filed Sep 9, 2019 22:27 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 4,712 $11.44 $53,905.28
Disclosure

SEC source: 0001209191-19-048940 · doc4.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,563,879

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 06, 2019 Filed Sep 9, 2019 22:27 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 3,802 $10.38 $39,464.76
Disclosure

SEC source: 0001209191-19-048940 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,568,591

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 05, 2019 Filed Sep 9, 2019 22:27 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 3,100 $10.29 $31,899.00
Disclosure

SEC source: 0001209191-19-048940 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,572,393

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 29, 2019 Filed Aug 29, 2019 21:23 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 2,188 $10.14 $22,186.32
Disclosure

SEC source: 0001209191-19-047734 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,575,493

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.05 to $10.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 27, 2019 Filed Aug 29, 2019 21:23 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 500 $10.23 $5,115.00
Disclosure

SEC source: 0001209191-19-047734 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,577,681

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.05 to $10.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 09, 2019 Filed Aug 9, 2019 21:20 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 2,773 $10.21 $28,312.33
Disclosure

SEC source: 0001209191-19-045382 · doc4.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,578,181

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 08, 2019 Filed Aug 9, 2019 21:20 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 3,118 $10.76 $33,549.68
Disclosure

SEC source: 0001209191-19-045382 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,580,954

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.48 to $11.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 07, 2019 Filed Aug 9, 2019 21:20 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 422 $10.28 $4,338.16
Disclosure

SEC source: 0001209191-19-045382 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,584,072

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.07 to $10.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 06, 2019 Filed Aug 6, 2019 22:14 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 2,602 $10.28 $26,748.56
Disclosure

SEC source: 0001209191-19-044881 · doc4.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,584,494

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 05, 2019 Filed Aug 6, 2019 22:14 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 1,679 $10.65 $17,881.35
Disclosure

SEC source: 0001209191-19-044881 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,587,096

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.28 to $10.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 02, 2019 Filed Aug 6, 2019 22:14 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 1,969 $10.78 $21,225.82
Disclosure

SEC source: 0001209191-19-044881 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,588,775

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.25 to $11.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 01, 2019 Filed Aug 1, 2019 21:41 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 1,953 $11.97 $23,377.41
Disclosure

SEC source: 0001209191-19-044073 · doc4.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,590,744

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.69 to $12.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 31, 2019 Filed Aug 1, 2019 21:41 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 3,500 $12.02 $42,070.00
Disclosure

SEC source: 0001209191-19-044073 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,592,697

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.71 to $12.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 30, 2019 Filed Aug 1, 2019 21:41 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 4,885 $11.83 $57,789.55
Disclosure

SEC source: 0001209191-19-044073 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,596,197

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.72 to $12.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 29, 2019 Filed Jul 29, 2019 23:57 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 630 $12.52 $7,887.60
Disclosure

SEC source: 0001209191-19-043586 · doc4.xml · nonDerivative · entry 4

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,601,082

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.34 to $12.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 29, 2019 Filed Jul 29, 2019 23:57 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 8,551 $11.62 $99,362.62
Disclosure

SEC source: 0001209191-19-043586 · doc4.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,601,712

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.13 to $12.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 26, 2019 Filed Jul 29, 2019 23:57 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 1,902 $10.65 $20,256.30
Disclosure

SEC source: 0001209191-19-043586 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,610,263

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.29 to $10.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 25, 2019 Filed Jul 29, 2019 23:57 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 975 $10.23 $9,974.25
Disclosure

SEC source: 0001209191-19-043586 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,612,165

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.03 to $10.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 24, 2019 Filed Jul 24, 2019 23:13 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 502 $10.19 $5,115.38
Disclosure

SEC source: 0001209191-19-043133 · doc4.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,613,140

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.02 to $10.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 23, 2019 Filed Jul 24, 2019 23:13 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 1,600 $10.28 $16,448.00
Disclosure

SEC source: 0001209191-19-043133 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,613,642

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.25 to $10.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 22, 2019 Filed Jul 24, 2019 23:13 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 700 $10.17 $7,119.00
Disclosure

SEC source: 0001209191-19-043133 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,615,242

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.10 to $10.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 19, 2019 Filed Jul 19, 2019 22:06 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 1,800 $10.28 $18,504.00
Disclosure

SEC source: 0001209191-19-042811 · doc4.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,615,942

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.12 to $10.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 18, 2019 Filed Jul 19, 2019 22:06 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 6,700 $10.27 $68,809.00
Disclosure

SEC source: 0001209191-19-042811 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,617,742

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.005 to $10.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 17, 2019 Filed Jul 19, 2019 22:06 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 2,300 $10.55 $24,265.00
Disclosure

SEC source: 0001209191-19-042811 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,624,442

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.435 to $10.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 16, 2019 Filed Jul 16, 2019 22:48 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 2,200 $10.92 $24,024.00
Disclosure

SEC source: 0001209191-19-042276 · doc4.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,626,742

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.71 to $11.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 15, 2019 Filed Jul 16, 2019 22:48 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 5,290 $10.89 $57,608.10
Disclosure

SEC source: 0001209191-19-042276 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,628,942

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.575 to $11.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 12, 2019 Filed Jul 16, 2019 22:48 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 3,000 $11.01 $33,030.00
Disclosure

SEC source: 0001209191-19-042276 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,634,232

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.77 to $11.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 11, 2019 Filed Jul 11, 2019 21:19 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 1,640 $11.16 $18,302.40
Disclosure

SEC source: 0001209191-19-041852 · doc4.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,637,232

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.09 to $11.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 10, 2019 Filed Jul 11, 2019 21:19 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 9,105 $11.57 $105,344.85
Disclosure

SEC source: 0001209191-19-041852 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,638,872

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.16 to $12.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 09, 2019 Filed Jul 11, 2019 21:19 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 2,467 $11.88 $29,307.96
Disclosure

SEC source: 0001209191-19-041852 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,647,977

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.39 to $12.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 08, 2019 Filed Jul 8, 2019 20:55 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 5,675 $11.06 $62,765.50
Disclosure

SEC source: 0001209191-19-041426 · doc4.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,650,444

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.83 to $11.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 05, 2019 Filed Jul 8, 2019 20:55 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 3,954 $11.41 $45,115.14
Disclosure

SEC source: 0001209191-19-041426 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,656,119

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 03, 2019 Filed Jul 8, 2019 20:55 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 2,900 $11.50 $33,350.00
Disclosure

SEC source: 0001209191-19-041426 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,660,073

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.01 to $11.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 02, 2019 Filed Jul 2, 2019 21:48 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 6,239 $11.57 $72,185.23
Disclosure

SEC source: 0001209191-19-040513 · doc4.xml · nonDerivative · entry 4

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,662,973

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.32 to $12.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:48 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 15,421 $12.00 $185,052.00
Disclosure

SEC source: 0001209191-19-040513 · doc4.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,669,212

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.62 to $12.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 28, 2019 Filed Jul 2, 2019 21:48 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 8,359 $11.41 $95,376.19
Disclosure

SEC source: 0001209191-19-040513 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,684,633

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.01 to $11.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 28, 2019 Filed Jul 2, 2019 21:48 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 3,502 $10.63 $37,226.26
Disclosure

SEC source: 0001209191-19-040513 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,692,992

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 25, 2019 Filed Jun 27, 2019 22:11 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 210 $10.04 $2,108.40
Disclosure

SEC source: 0001209191-19-039343 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,696,494

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.02 to $10.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 13, 2019 Filed Jun 14, 2019 21:34 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 1,431 $10.03 $14,352.93
Disclosure

SEC source: 0001209191-19-037224 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,696,704

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 12, 2019 Filed Jun 14, 2019 21:34 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 700 $8.86 $6,202.00
Disclosure

SEC source: 0001209191-19-037224 · doc4.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,698,135

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.775 to $8.905, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 11, 2019 Filed Jun 11, 2019 22:06 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 838 $8.89 $7,449.82
Disclosure

SEC source: 0001209191-19-036181 · doc4.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,698,835

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.74 to $8.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 10, 2019 Filed Jun 11, 2019 22:06 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 SaleCommon Stock 2,100 $8.79 $18,459.00
Disclosure

SEC source: 0001209191-19-036181 · doc4.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,699,673

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $8.275 to $9.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.